Form 8-K

8-K — Structure Therapeutics Inc.

Accession: 0001104659-26-092017

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0001888886

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2622407d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622407d1_ex99-1.htm)

GRAPHIC (tm2622407d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622407d1_8k.htm · Sequence: 1

false

0001888886

True

0001888886

2026-08-06

0001888886

gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember

2026-08-06

0001888886

gpcr:OrdinarySharesParValue0.0001PerShareMember

2026-08-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or

15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 6, 2026

Structure

Therapeutics Inc.

(Exact name of registrant as specified in its

charter)

Cayman

Islands

001-41608

98-1480821

(State

or other jurisdiction

of incorporation)

(Commission

File

Number)

(IRS Employer

Identification

No.)

601

Gateway Blvd., Suite 900

South

San Francisco, California

94080

(Address

of principal executive offices)

(Zip

Code)

(Registrant’s

telephone number, including area code): (650) 457-1978

Not Applicable

(Former name or former address, if changed

since last report)

Check the appropriate box below if the

Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions (see General Instruction A.2. below):

Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title

of Each Class

Name Of Each Exchange

Trading Symbol(s)

On Which

Registered

American

Depositary Shares (ADSs), each representing three

ordinary shares, par value $0.0001 per ordinary share

GPCR

Nasdaq

Global Market

Ordinary

shares, par value $0.0001 per share*

True

Nasdaq

Global Market*

* Not for trading, but only in connection with the registration of

the American Depositary Shares

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any

new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, Structure Therapeutics Inc. (the

“Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter

ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated

herein by reference.

The information in this Current Report on Form 8-K (including

Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the

“Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference

into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific

reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release dated August 6, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Structure Therapeutics Inc.

Date: August 6, 2026

By:

/s/ Raymond Stevens

Raymond Stevens, Ph.D.

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622407d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Structure Therapeutics Reports Second Quarter

2026 Financial Results and Recent Highlights

First patients dosed in aleniglipron (oral small

molecule GLP-1 receptor agonist)

Phase 3 ACCOMPLISH program for chronic weight management

Data from Phase 1 SAD clinical trial of ACCG-2671

(oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on track for Q3 2026

Topline 72-week aleniglipron ACCESS OLE data

on track for Q3 2026;

data from body composition, type 2 diabetes/obesity and SWITCH clinical trials

on track for Q4 2026

Appointed metabolic commercial industry veteran

John Berrios as Chief Commercial Officer

Cash, cash equivalents and short-term investments

of $1.3 billion as of June 30, 2026

expected to fund projected operations and key clinical milestones through 2028

SAN FRANCISCO, August 6, 2026

– Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral

small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the second quarter ended

June 30, 2026 and provided a business update including the initiation of the Phase 3 ACCOMPLISH program evaluating aleniglipron for

chronic weight management.

“Dosing the first patients in ACCOMPLISH-1 and -2 is a defining

milestone for Structure as we advance aleniglipron, our potentially best-in-class oral GLP-1 receptor agonist, toward potential registration,”

said Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics. “As we enter this next stage of development, the

appointment of John Berrios as our Chief Commercial Officer adds tremendous experience in obesity, diabetes, market access and commercialization

to our senior leadership team, particularly given his leadership role in the GLP-1 space.”

“Obesity is a chronic disease, and people need treatment options

that can adapt to their individual goals over time,” continued Dr. Stevens. “We are building a comprehensive portfolio

of oral small molecule medicines designed to provide greater choice, flexibility and accessibility across the treatment journey, from

initial weight loss through long-term weight maintenance. As an important component of this strategy, we are advancing ACCG-2671, our

potentially first-in-class oral small molecule dual amylin and calcitonin receptor agonist and remain on track to report initial single

ascending dose data and initiate a multiple ascending dose clinical trial in the third quarter. We also look forward to initiating our

combination GLP-1 and amylin receptor agonist clinical trial later this year. We believe these programs have the potential to provide

meaningful, sustained weight and metabolic benefits through convenient and accessible oral treatment options.”

Recent and Upcoming Milestones

Aleniglipron – Oral Small Molecule Selective Glucagon-Like

Peptide 1 (GLP-1) Receptor Agonist for Chronic Weight Management

The Company announced that the first patients have been dosed in the

Phase 3 ACCOMPLISH program, which includes two clinical trials evaluating aleniglipron, a once-daily oral small molecule GLP-1 receptor

agonist.

· ACCOMPLISH-1 is evaluating aleniglipron in adults living with obesity or

overweight with a weight-related comorbidity and will enroll up to 3,600 patients; ACCOMPLISH-2 is evaluating aleniglipron in adults living

with obesity or overweight and type 2 diabetes mellitus (T2DM) and will enroll up to 1,100 patients.

· ACCOMPLISH-1 and ACCOMPLISH-2 are randomized, double-blind, placebo-controlled

clinical trials designed to evaluate the long-term efficacy and safety of three maintenance doses of aleniglipron. Participants in the

clinical trials will be randomized to one of four treatment arms, with three active doses (45 mg, 90 mg or 180 mg) or placebo. Patients

will begin treatment at a 2.5 mg starting dose with 4-week titration increments.

· Together, the ACCOMPLISH clinical trials are designed to support global regulatory

submissions for aleniglipron in chronic weight management.

· Additional

information about ACCOMPLISH-1 and ACCOMPLISH-2, including endpoints, eligibility criteria

and enrolling sites, is available at ClinicalTrials.gov under identifiers NCT07654361

and NCT07654374, respectively.

In June 2026, data from the Phase

2b ACCESS clinical trial of aleniglipron were published in Nature Medicine and highlighted in an oral presentation at the

American Diabetes Association's (ADA) 86th Scientific Sessions. The publication and presentation detailed dose-dependent, clinically

meaningful and statistically significant reductions in body weight, with continued weight loss beyond 36 weeks and up to 16.2% at 44

weeks observed during the open-label extension. The tolerability profile reflected the well-known gastrointestinal-related adverse events

typical of the GLP-1 class, with a favorable overall discontinuation rate of 10.4%.

Structure plans to report new data from the following aleniglipron

clinical trials in the second half of 2026:

· The ACCESS Open Label Extension (OLE) clinical trial is evaluating the tolerability

of the dose titration regimen that includes a starting dose of 2.5 mg in placebo crossover patients. The clinical trial will be completed

after a total of 72 weeks of treatment, where some participants have been exposed to 180 mg for a certain period of time. Data are expected

in Q3 2026.

· The Body Composition clinical trial is assessing the effect of aleniglipron

on body fat loss over a 44-week evaluation period. Data are expected in Q4 2026.

· The clinical trial in patients with T2DM with obesity/overweight is evaluating

the potential for including participants with T2DM in the Phase 3 program. Data are expected in Q4 2026.

· The SWITCH clinical trial is assessing the transition from an approved injectable

GLP-1 receptor agonist to once-daily oral aleniglipron for long-term weight loss maintenance. Data are expected in Q4 2026.

Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists

· ACCG-2671, an oral small molecule dual amylin and calcitonin receptor agonist,

continues to be evaluated in an ongoing Phase 1 single ascending dose (SAD) clinical trial assessing safety, tolerability, pharmacokinetics

and food effect in healthy adult participants. Initial data, along with initiation of a multiple ascending dose (MAD) clinical trial,

remain on track for Q3 2026.

· The Company plans to initiate a Phase 1 clinical trial of its second oral

small molecule dual amylin and calcitonin receptor agonist candidate, ACCG-3535, in Q4 2026, demonstrating continued leadership in the

oral small molecule amylin field.

Combination of Oral Small Molecule GLP-1 and Amylin Receptor Agonists

· Preclinical

combination data of aleniglipron and ACCG-2671 were presented at the ADA Scientific Sessions

in June 2026 demonstrating additional weight loss compared to each monotherapy in non-human

primates. A combination clinical trial is expected to be initiated in Q4 2026.

Appointment of John Berrios as Chief Commercial Officer (CCO)

· Structure has appointed John Berrios as its CCO. Mr. Berrios brings

more than 25 years of commercial leadership experience across the biopharmaceutical industry, with expertise spanning commercial strategy,

sales, marketing, operations and market access. Most recently, he served as Head of U.S. Sales Strategy and Innovation for Obesity and

Diabetes at Novo Nordisk and was instrumental in leading the strategic planning and commercial launch of its obesity and diabetes portfolio.

Previously, he held senior leadership roles at Bayer Pharmaceuticals and AstraZeneca, where he led commercial organizations and supported

the launch and growth of multiple products across obesity, diabetes, cardiovascular disease, and other therapeutic areas.

Second Quarter 2026 Financial Highlights

Cash Position: Cash, cash

equivalents and short-term investments totaled $1.3 billion as of June 30, 2026, compared to $1.5 billion as of March 31, 2026.

The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key clinical milestones

through the end of 2028, including costs related to the ongoing aleniglipron ACCESS OLE, ACCESS II extension clinical trial, the supplementary

clinical trials, and Phase 3 registrational program in chronic weight management, but excludes additional costs related to pre-commercialization

activities including commercial manufacturing.

Research and Development (R&D)

Expenses: R&D expenses for the second quarter of 2026 were $100.1 million, as compared to $54.7 million for the same period

in 2025. The increase in research and development expenses was primarily due to increases related to clinical trial costs, preclinical

research and development expenses, and employee expenses (primarily due to an increase in personnel).

General and Administrative (G&A)

Expenses: G&A expenses for the second quarter of 2026 were $18.6 million, as compared to $15.7 million for the same period

in 2025. The increase in G&A expenses was primarily due to increases in employee expenses as the Company expanded its infrastructure

to drive and support the growth in operations as a publicly-traded company, and increases in professional services.

Net Loss: Net loss for

the second quarter of 2026 totaled $106.2 million, with non-cash share-based compensation expense of $12.6 million, compared to a net

loss of $61.7 million for the same period in 2025, with non-cash share-based compensation expense of $7.5 million.

About Structure Therapeutics

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical

company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant

unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted

pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability

limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For

additional information, please visit www.structuretx.com.

Forward Looking Statements

This

press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the

Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release

are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s

future plans and prospects, including its research and development activities; the design, initiation, enrollment, conduct, timing and

completion of the Company’s clinical trials, including the aleniglipron Phase 3 ACCOMPLISH program, the ACCG-2671 multiple ascending

dose (MAD) clinical trial, the ACCG-3535 Phase 1 clinical trial and the combination amylin/GLP-1 clinical trial and the timing of topline,

interim, or additional data readouts from the Phase 1 single ascending dose (SAD) clinical trial of ACCG-2671, and the aleniglipron ACCESS

OLE, Body Composition, SWITCH and type 2 diabetes/obesity clinical trials; the Company’s expectation that the aleniglipron ACCOMPLISH

clinical trials will be sufficient to support global regulatory submissions for aleniglipron in chronic weight management; any expectations

regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience,

expected effects, competitive positioning (including any characterization of a product candidate as potential “best-in-class”

or “first-in-class”) and future application of aleniglipron, ACCG-2671, ACCG-3535 and any other of the Company’s investigational

compounds; any presumption that topline, interim or preliminary data will be representative of, or predictive of, final data from other

or later clinical trials; the Company’s ability to support global regulatory submissions for its product candidates and to obtain,

maintain and expand regulatory approvals; and the Company’s expectations regarding its cash, cash equivalents and short-term investments

and its estimated cash runway, including its ability to fund projected operations and clinical milestones through the end of 2028. In

addition, when or if used in this press release, the words and phrases “continue,” “could,” “anticipated,”

“believe,” “expect,” “may,” “on track,” “plan,” “potential,”

“project,” “remain,” “target,” “suggests,” “to be,” “to begin,”

“will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements.

Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations

reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be

correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ

materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties,

which include, without limitation: the risk that topline, interim or preliminary data the Company reports are based on a preliminary

analysis of then-available efficacy and safety data, and such data may change following a more comprehensive review of the data related

to the applicable clinical trial, and such topline, interim or preliminary data may not accurately reflect the complete or final results

of a clinical trial; the preliminary nature of clinical results given the length of the applicable clinical trial and sample size, and

the fact that results from earlier clinical trials are not necessarily predictive of future results; potential delays in the commencement,

enrollment, conduct or completion of the Company’s planned and ongoing clinical trials, including the Phase 3 ACCOMPLISH program;

the risk that clinical trial results may not support further development or regulatory approval of aleniglipron, ACCG-2671, ACCG-3535,

or the Company’s other therapeutic candidates; the Company’s ability to obtain and maintain regulatory approval of, and ultimately

successfully commercialize, its therapeutic candidates; the effect of competitive products or therapeutic approaches on the commercial

value of the Company’s product candidates; the Company’s ability to fund its development activities and achieve its development

goals; and other risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission

(SEC), including the Company’s most recent Quarterly Report on Form 10-Q, and other reports the Company has filed or may file

with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they

were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update

such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by

law.

Investors:

Corey Davis,

Ph.D.

LifeSci Advisors, LLC

212-915-2577

cdavis@lifesciadvisors.com

Jen Robinson

Structure Therapeutics Inc.

ir@structuretx.com

Media:

Dan Budwick

1AB

Dan@1abmedia.com

STRUCTURE THERAPEUTICS INC.

Condensed Consolidated Statements of Operations

(unaudited)

(In thousands)

THREE MONTHS ENDED

SIX MONTHS ENDED

JUNE 30,

2026

2025

2026

2025

Operating expenses:

Research and development

$ 100,057

$ 54,710

$ 166,564

$ 97,577

General and administrative

18,573

15,741

41,445

29,185

Total operating expenses

118,630

70,451

208,009

126,762

Loss from operations

(118,630 )

(70,451 )

(208,009 )

(126,762 )

Interest and other income, net

12,705

8,929

26,306

18,505

Loss before provision for income taxes

(105,925 )

(61,522 )

(181,703 )

(108,257 )

Provision for (benefit from) income taxes

234

139

424

237

Net loss

$ (106,159 )

$ (61,661 )

$ (182,127 )

$ (108,494 )

STRUCTURE THERAPEUTICS INC.

Condensed Consolidated Balance Sheet Data

(unaudited)

(In thousands)

JUNE 30,

DECEMBER 31,

2026

2025

Assets

Current assets:

Cash, cash equivalents and short-term investments

$ 1,342,658

$ 1,446,197

Prepaid expenses and other current assets

29,370

124,106

Total current assets

1,372,028

1,570,303

Property and equipment, net

6,332

6,653

Operating right-of-use assets

6,060

6,245

Other non-current assets

40,995

717

Total assets

$ 1,425,415

$ 1,583,918

Liabilities and shareholders’ equity

Current liabilities:

Accounts payable

$ 11,131

$ 13,864

Accrued expenses and other current liabilities

52,387

46,543

Operating lease liabilities, current portion

2,595

2,878

Total current liabilities

66,113

63,285

Operating lease liabilities, net of current portion

3,633

3,609

Other non-current liabilities

1,265

647

Total liabilities

71,011

67,541

Total shareholders’ equity

1,354,404

1,516,377

Total liabilities and shareholders’ equity

$ 1,425,415

$ 1,583,918

GRAPHIC

Filename: tm2622407d1_ex99-1img001.jpg · Sequence: 7

Binary file (25043 bytes)

Download tm2622407d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 06, 2026

Document Information [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 06, 2026

Entity File Number

001-41608

Entity Registrant Name

Structure

Therapeutics Inc.

Entity Central Index Key

0001888886

Entity Tax Identification Number

98-1480821

Entity Incorporation, State or Country Code

Entity Address, Address Line One

601

Gateway Blvd.

Entity Address, Address Line Two

Suite 900

Entity Address, City or Town

South

San Francisco

Entity Address, State or Province

Entity Address, Postal Zip Code

94080

City Area Code

650

Local Phone Number

457-1978

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

American Depositary Shares Adss Each Representing Three Ordinary Shares Par Value 0. 0001 Per Ordinary Share [Member]

Document Information [Line Items]

Title of 12(b) Security

American

Depositary Shares (ADSs), each representing three

ordinary shares, par value $0.0001 per ordinary share

Trading Symbol

GPCR

Security Exchange Name

NASDAQ

Ordinary Shares Par Value 0. 0001 Per Share [Member]

Document Information [Line Items]

Title of 12(b) Security

Ordinary

shares, par value $0.0001 per share*

No Trading Symbol Flag

true

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true only for a security having no trading symbol.

+ References

No definition available.

+ Details

Name:

dei_NoTradingSymbolFlag

Namespace Prefix:

dei_

Data Type:

dei:trueItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=gpcr_AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=gpcr_OrdinarySharesParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: